{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:34:44Z","timestamp":1777401284222,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>The increasing prevalence of obesity among individuals with type 1 diabetes mellitus (T1DM) presents a significant clinical challenge, as it exacerbates insulin resistance, impairs glycemic control, and increases cardiometabolic risk. While obesity in T1DM is influenced by both genetic and environmental factors, recent evidence highlights the role of the gut-brain axis in metabolic regulation. This review explores the complex relationship between obesity and T1DM, the role of the gut-brain axis in metabolic dysregulation, and current weight management strategies, highlighting the need for further research to optimize treatment outcomes in this unique patient population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Key gastrointestinal hormones, including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and amylin, play essential roles in appetite control, energy balance, and glucose metabolism, yet their dysregulation in T1DM remains poorly understood. Addressing obesity requires a multifaceted approach, including lifestyle modifications, pharmacotherapy with GLP-1 receptor agonists (GLP-1RAs), and bariatric surgery (BS). Although limited, accumulating evidence regarding the use of liraglutide, semaglutide and tirzepatide in T1DM begin to highlight the safety and effectiveness of these molecules in this subset of patients as well.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Lifestyle modifications, GLP-1 RAs based pharmacotherapy and BS have emerged as potential strategies to address obesity in patients with T1DM. Initial findings point to potential improvements in both metabolic health and glycemic control, but further exploration of their role in the co-occurrence of obesity and T1DM remains limited. Ongoing research is crucial to better understand how the gut-brain axis influences weight regulation in T1DM and to determine the sustained benefits and risks of these emerging therapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s13679-025-00654-8","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T02:41:04Z","timestamp":1753411264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?"],"prefix":"10.1007","volume":"14","author":[{"given":"Georgia","family":"Argyrakopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evdoxia","family":"Gitsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kokkinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"654_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","volume":"10","author":"GA Gregory","year":"2022","unstructured":"Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10:741\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"654_CR2","doi-asserted-by":"crossref","unstructured":"Kueh MTW, Chew NWS, Al-Ozairi E, Roux CW. le. The emergence of obesity in type 1 diabetes. Int J Obes (Lond). 2024;48:289\u2013301.","DOI":"10.1038\/s41366-023-01429-8"},{"key":"654_CR3","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2147\/DMSO.S223618","volume":"14","author":"N Vilarrasa","year":"2021","unstructured":"Vilarrasa N, Jose PS, Rubio M\u00c1, Lecube A. Obesity in patients with type 1 diabetes: links, risks and management challenges. Diabetes Metab Syndr Obes. 2021;14:2807\u201327.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"654_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000496183","volume":"12","author":"DD Schutz","year":"2019","unstructured":"Schutz DD, Busetto L, Dicker D, Farpour-Lambert N, Pryke R, Toplak H, et al. European practical and Patient-Centred guidelines for adult obesity management in primary care. Obes Facts. 2019;12:40\u201366.","journal-title":"Obes Facts"},{"key":"654_CR5","doi-asserted-by":"publisher","first-page":"890833","DOI":"10.3389\/fendo.2022.890833","volume":"13","author":"S Ci\u0119\u017cki","year":"2022","unstructured":"Ci\u0119\u017cki S, Kurpiewska E, Bossowski A, G\u0142owi\u0144ska-Olszewska B. Multi-Faceted influence of obesity on type 1 diabetes in Children - From disease pathogenesis to complications. Front Endocrinol (Lausanne). 2022;13:890833.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"654_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1464-5491.2010.03160.x","volume":"28","author":"KC Verbeeten","year":"2011","unstructured":"Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and subsequent type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2011;28:10\u20138.","journal-title":"Diabet Med"},{"key":"654_CR7","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1177\/0145721715607642","volume":"41","author":"L Hieronymus","year":"2015","unstructured":"Hieronymus L, Griffin S. Role of Amylin in type 1 and type 2 diabetes. Diabetes Educ. 2015;41:S47\u201356.","journal-title":"Diabetes Educ"},{"key":"654_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1098\/rstb.2006.1858","volume":"361","author":"SC Woods","year":"2006","unstructured":"Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and Amylin. Philos Trans R Soc Lond B Biol Sci. 2006;361:1219\u201335.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"654_CR9","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1210\/jcem.87.6.8738","volume":"87","author":"PJ English","year":"2002","unstructured":"English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JPH. Food fails to suppress Ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002;87:2984.","journal-title":"J Clin Endocrinol Metab"},{"key":"654_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00125-003-1258-6","volume":"47","author":"C Holdstock","year":"2004","unstructured":"Holdstock C, Ludvigsson J, Karlsson FA. Abnormal Ghrelin secretion in new onset childhood type 1 diabetes. Diabetologia. 2004;47:150\u20131.","journal-title":"Diabetologia"},{"key":"654_CR11","first-page":"327","volume":"81","author":"B Willms","year":"1996","unstructured":"Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81:327\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"654_CR12","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","volume":"66","author":"MA Nauck","year":"2023","unstructured":"Nauck MA, M\u00fcller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66:1780\u201395.","journal-title":"Diabetologia"},{"key":"654_CR13","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1210\/jc.2002-021873","volume":"88","author":"T Vilsb\u00f8ll","year":"2003","unstructured":"Vilsb\u00f8ll T, Krarup T, Sonne J, Madsbad S, V\u00f8lund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"654_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00125-018-4804-y","volume":"62","author":"C Thivolet","year":"2019","unstructured":"Thivolet C, Marchand L, Chikh K. Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide. Diabetologia. 2019;62:593\u20137.","journal-title":"Diabetologia"},{"key":"654_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000308168","volume":"73","author":"M Lodefalk","year":"2010","unstructured":"Lodefalk M, Carlsson-Skwirut C, Holst JJ, Aman J, Bang P. Effects of fat supplementation on postprandial GIP, GLP-1, Ghrelin and IGFBP-1 levels: a pilot study on adolescents with type 1 diabetes. Horm Res Paediatr. 2010;73:355\u201362.","journal-title":"Horm Res Paediatr"},{"key":"654_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.regpep.2004.06.003","volume":"128","author":"J Dupre","year":"2005","unstructured":"Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept. 2005;128:149\u201357.","journal-title":"Regul Pept"},{"key":"654_CR17","doi-asserted-by":"crossref","unstructured":"Delrue C, Speeckaert MM. Mechanistic pathways and clinical implications of GLP-1 receptor agonists in type 1 diabetes management. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25179351"},{"key":"654_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fendo.2020.00553","volume":"11","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Hwang SD, Lim S. Effects of Sodium-Glucose cotransporter Inhibitor\/Glucagon-Like Peptide-1 receptor agonist Add-On to insulin therapy on glucose homeostasis and body weight in patients with type 1 diabetes: A network Meta-Analysis. Front Endocrinol (Lausanne). 2020;11:553.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"654_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","volume":"4","author":"TF Dejgaard","year":"2016","unstructured":"Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4:221\u201332.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"654_CR20","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE Treat-to-target randomized trial. Diabetes Care. 2016;39:1702\u201310.","journal-title":"Diabetes Care"},{"key":"654_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2337\/dc15-1136","volume":"39","author":"ND Kuhadiya","year":"2016","unstructured":"Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, Batra M, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: A randomized Placebo-Controlled clinical trial of 12 weeks. Diabetes Care. 2016;39:1027\u201335.","journal-title":"Diabetes Care"},{"key":"654_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4158\/EP13065.OR","volume":"19","author":"ND Kuhadiya","year":"2013","unstructured":"Kuhadiya ND, Malik R, Bellini NJ, Patterson JL, Traina A, Makdissi A, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013;19:963\u20137.","journal-title":"Endocr Pract"},{"key":"654_CR23","doi-asserted-by":"publisher","unstructured":"Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU et al. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial. Diabetes Obes Metab [Internet]. 2020;22:492\u2013500. Available from: https:\/\/doi.org\/10.1111\/dom.13911","DOI":"10.1111\/dom.13911"},{"key":"654_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/19322968241291512","volume":"19","author":"VN Shah","year":"2025","unstructured":"Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, et al. Consensus report on Glucagon-Like Peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system. J Diabetes Sci Technol. 2025;19:191\u2013216.","journal-title":"J Diabetes Sci Technol"},{"key":"654_CR25","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/dom.14090","volume":"22","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22:1742\u201352.","journal-title":"Diabetes Obes Metab"},{"key":"654_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bcpt.13575","volume":"128","author":"A-M Wegeberg","year":"2021","unstructured":"Wegeberg A-M, Meldgaard T, Baek A, Drewes AM, Vyberg M, Jessen N, et al. Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes. Basic Clin Pharmacol Toxicol. 2021;128:773\u201382.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"654_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/oby.23677","volume":"31","author":"E Al-Ozairi","year":"2023","unstructured":"Al-Ozairi E, Irshad M, Taghadom E, Sojan L, Kandari JA, Alroudhan D, et al. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes. Obes (Silver Spring). 2023;31:716\u201323.","journal-title":"Obes (Silver Spring)"},{"key":"654_CR28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","volume":"76","author":"J Guyton","year":"2019","unstructured":"Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health Syst Pharm. 2019;76:1739\u201348.","journal-title":"Am J Health Syst Pharm"},{"key":"654_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1089\/dia.2023.0490","volume":"26","author":"SK Garg","year":"2024","unstructured":"Garg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther. 2024;26:184\u20139.","journal-title":"Diabetes Technol Ther"},{"key":"654_CR30","doi-asserted-by":"publisher","unstructured":"Mertens J, Winter HTD, Mazlom H, Peiffer FW, Dirinck El, Bochanen N et al. 751-P: Effect Of Once-weekly semaglutide on weight change and metabolic control in people with type 1 diabetes\u2014Six-months results from the real-world STEMT trial. Diabetes [Internet]. 2022;71:751-P. Available from: https:\/\/doi.org\/10.2337\/db22-751-P","DOI":"10.2337\/db22-751-P"},{"key":"654_CR31","doi-asserted-by":"publisher","first-page":"111593","DOI":"10.1016\/j.diabres.2024.111593","volume":"209","author":"BA Grassi","year":"2024","unstructured":"Grassi BA, Onetto MT, S\u00e1nchez C, Tapia N, Mena F. Effect of low dose semaglutide in people with type 1 diabetes and excess weight. Diabetes Res Clin Pract. 2024;209:111593.","journal-title":"Diabetes Res Clin Pract"},{"key":"654_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, Manghi FCP, Land\u00f3 LF, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"654_CR33","doi-asserted-by":"crossref","unstructured":"Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and safety of Tirzepatide in adults with type 1 diabetes: A proof of concept observational study. J Diabetes Sci Technol. 2024;19322968231223990.","DOI":"10.1177\/19322968231223991"},{"key":"654_CR34","doi-asserted-by":"publisher","unstructured":"Tama E, Bechenati D, Bennett P, Rivera Mcnallya, Fansa R et al. S,. 1660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes\u2014The Mayo Clinic Experience. Diabetes [Internet]. 2024;73:1660-P. Available from: https:\/\/doi.org\/10.2337\/db24-1660-P","DOI":"10.2337\/db24-1660-P"},{"key":"654_CR35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","volume":"18","author":"D Eisenberg","year":"2022","unstructured":"Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18:1345\u201356.","journal-title":"Surg Obes Relat Dis"},{"key":"654_CR36","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s11695-022-05980-7","volume":"32","author":"M Kermansaravi","year":"2022","unstructured":"Kermansaravi M, Valizadeh R, Jazi AD, Shahmiri SS, Martinez JAL, Mousavimaleki A, et al. Current status of metabolic\/bariatric surgery in type 1 diabetes mellitus: an updated systematic review and Meta-analysis. Obes Surg. 2022;32:1726\u201333.","journal-title":"Obes Surg"},{"key":"654_CR37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2337\/dc15-2732","volume":"39","author":"JP Kirwan","year":"2016","unstructured":"Kirwan JP, Aminian A, Kashyap SR, Burguera B, Brethauer SA, Schauer PR. Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care. 2016;39:941\u20138.","journal-title":"Diabetes Care"},{"key":"654_CR38","doi-asserted-by":"publisher","first-page":"204201881882220","DOI":"10.1177\/2042018818822207","volume":"10","author":"Z Landau","year":"2019","unstructured":"Landau Z, Kowen-Sandbank G, Jakubowicz D, Raziel A, Sakran N, Zaslavsky-Paltiel I, et al. Bariatric surgery in patients with type 1 diabetes: special considerations are warranted. Ther Adv Endocrinol Metab. 2019;10:2042018818822207.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"654_CR39","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s11695-015-1999-6","volume":"26","author":"H Ashrafian","year":"2016","unstructured":"Ashrafian H, Harling L, Toma T, Athanasiou C, Nikiteas N, Efthimiou E, et al. Type 1 diabetes mellitus and bariatric surgery: A systematic review and Meta-Analysis. Obes Surg. 2016;26:1697\u2013704.","journal-title":"Obes Surg"},{"key":"654_CR40","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1007\/s11695-022-06321-4","volume":"32","author":"C Parmar","year":"2022","unstructured":"Parmar C, Appel S, Lee L, Ribeiro R, Sakran N, Pouwels S. Choice of bariatric surgery in patients with obesity And type 1 diabetes mellitus? An Up-to-Date systematic review. Obes Surg. 2022;32:3992\u20134006.","journal-title":"Obes Surg"},{"key":"654_CR41","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/oby.20992","volume":"23","author":"S Maraka","year":"2015","unstructured":"Maraka S, Kudva YC, Kellogg TA, Collazo-Clavell ML, Mundi MS. Bariatric surgery and diabetes: implications of type 1 versus insulin-requiring type 2. Obes (Silver Spring). 2015;23:552\u20137.","journal-title":"Obes (Silver Spring)"},{"key":"654_CR42","doi-asserted-by":"publisher","first-page":"525909","DOI":"10.3389\/fendo.2020.525909","volume":"11","author":"E Korakas","year":"2020","unstructured":"Korakas E, Kountouri A, Raptis A, Kokkinos A, Lambadiari V. Bariatric surgery and type 1 diabetes: unanswered questions. Front Endocrinol (Lausanne). 2020;11:525909.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00654-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:24:25Z","timestamp":1757283865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00654-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00654-8","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"16 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"61"}}